Boston Scientific (BSX) Stock Forecast & Price Target

$105.63 +0.28 (+0.27%)

Closing price 02/19/2025 03:59 PM Eastern

Extended Trading

$104.89 -0.74 (-0.70%)

As of 02/19/2025 07:57 PM Eastern

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 23 Analyst Ratings

Sell
0

Hold
1

Buy
22

Based on 23 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Buy." Out of the 23 analysts, 1 has given a hold rating, 21 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$107.39
1.67% Upside

According to the 23 analysts' twelve-month price targets for Boston Scientific, the average price target is $107.39. The highest price target for BSX is $130.00, while the lowest price target for BSX is $86.00. The average price target represents a forecasted upside of 1.67% from the current price of $105.63.

Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

BSX Analyst Ratings Over Time

Type	Current Forecast 2/21/24 to 2/20/25	1 Month Ago 1/22/24 to 1/21/25	3 Months Ago 11/23/23 to 11/22/24	1 Year Ago 2/21/23 to 2/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	21 Buy rating(s)	20 Buy rating(s)	19 Buy rating(s)	17 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$107.39	$97.26	$93.39	$66.05
Forecasted Upside	1.67% Upside	-3.60% Downside	3.77% Upside	0.45% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.67% Upside	28,068.17% Upside	12.69% Upside
News Sentiment Rating	Positive News See Recent BSX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/10/2025	Barclays 3 of 5 stars	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$111.00 ➝ $118.00	+12.03%
2/7/2025	UBS Group 4 of 5 stars	Danielle Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$105.00 ➝ $130.00	+23.64%
2/6/2025	Raymond James 4 of 5 stars	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Strong-Buy ➝ Strong-Buy	$119.00 ➝ $122.00	+15.87%
2/6/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$100.00 ➝ $115.00	+9.25%
2/6/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$105.00 ➝ $116.00	+10.20%
2/6/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$100.00 ➝ $118.00	+12.51%
2/6/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$107.00 ➝ $122.00	+16.25%
2/6/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$100.00 ➝ $120.00	+14.34%
2/6/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/3/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$95.00 ➝ $115.00	+11.65%
Get the Latest News and Ratings for BSX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.
1/10/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$108.00	+12.64%
12/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$100.00 ➝ $110.00	+22.21%
12/16/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$100.00 ➝ $110.00	+21.21%
12/12/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$100.00 ➝ $110.00	+21.11%
12/9/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$98.00 ➝ $101.00	+12.92%
10/24/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$92.00 ➝ $100.00	+16.41%
10/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$100.00 ➝ $110.00	+25.79%
10/22/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+13.39%
10/14/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$84.00 ➝ $93.00	+6.72%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$82.00 ➝ $90.00	+7.80%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$90.00 ➝ $91.00	+17.03%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+20.05%
5/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $95.00	+26.51%
2/1/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$58.00 ➝ $68.00	+5.44%
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Initiates
6/30/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$64.00	+20.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:16 AM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, February 17, 2025. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

Recent upgrades from multiple analysts, including UBS Group raising the price target to $130.00, indicate strong confidence in the company's growth potential.
The stock is currently trading at $106.20, which is close to the consensus price target of $107.39, suggesting it may be undervalued and could see upward movement.
Boston Scientific Co. has received a majority of buy ratings from analysts, with twenty-two analysts rating it as a buy, reflecting positive market sentiment.
Institutional investors hold 89.07% of the stock, indicating strong institutional confidence and support for the company's future performance.
Recent developments in their medical device offerings, particularly in the MedSurg and Cardiovascular segments, position the company well in a growing healthcare market.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

Despite positive ratings, one analyst has assigned a hold rating, suggesting some caution among market experts regarding the stock's immediate performance.
The stock's recent trading volume of 3,966,417 shares is below its average volume of 6,179,673, which may indicate reduced investor interest or liquidity issues.
Increased competition in the medical device industry could impact Boston Scientific Co.'s market share and profitability in the long term.
Potential regulatory challenges in the healthcare sector could pose risks to the company's operations and product approvals.
Market volatility and economic uncertainties may affect investor sentiment and stock performance, leading to potential declines in share value.

BSX Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $107.39, with a high forecast of $130.00 and a low forecast of $86.00.
: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There is currently 1 hold rating, 21 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BSX shares.
: According to analysts, Boston Scientific's stock has a predicted upside of 1.67% based on their 12-month stock forecasts.
: Over the previous 90 days, Boston Scientific's stock had 1 upgrade by analysts.
: Boston Scientific has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Boston Scientific more than other "medical" companies. The consensus rating for Boston Scientific is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BSX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:BSX) was last updated on 2/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boston Scientific (BSX) Stock Forecast & Price Target